Agios Medical Booth
American Society of Clinical Oncology Annual Meeting 2020
IDH Mutations in Cancer
At Agios, our lead oncology programs are focused on cancers with a mutated isocitrate dehydrogenase (IDH) protein. IDH mutations occur in a wide range of blood and solid tumor cancers, including acute myeloid leukemia (AML), cholangiocarcinoma and glioma. Normally, IDH enzymes help to break down nutrients and generate energy for cells. When mutated, IDH creates a molecule that alters the cells’ genetic programming, and instead of maturing, the cells remain primitive and proliferate quickly. Agios believes that targeting mutated IDH may have the potential to benefit the subset of patients with tumors that carry IDH mutations.
IDH Inhibition Mechanism of Action
IDH Mutation Testing
Explore the role of IDH mutations in mIDH-positive cancers and the importance of molecular profiling.
Find out more about IDH mutations in hematologic malignancies and solid tumors.
Ongoing Clinical Trials

INDIGO
Phase 3 Study of Vorasidenib in Patients with Residual or Recurrent Grade 2 Glioma with an IDH1 or IDH2 Mutation
Download INDIGO Trial Card
AGILE
Phase 3 Study of Ivosidenib in Combination with Azacitidine in Adult Patients with Previously Untreated AML with an IDH1 Mutation
Download AGILE Trial Card
Myelodysplastic Syndrome (MDS) Phase 1 Study
Ongoing Phase 1 Expansion Arm Evaluating Ivosidenib in Adult Patients with Relapsed or Refractory MDS with an IDH1 Mutation
Download MDS Trial CardASCO 2020 Presentations and Posters
All oral and poster presentations will be available on demand for registered meeting attendees on the ASCO conference website beginning on May 29 at 8:00 a.m. ET.
Oral Presentations
Vorasidenib (VOR; AG-881), an inhibitor of mutant IDH1 and IDH2, in patients (pts) with recurrent/progressive glioma: Updated results from the phase I non-enhancing glioma population
Abstract: 2804
Phase Ib/II Study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor Venetoclax +/-azacitidine in IDH1-mutated hematologic malignancies (Investigator-sponsored trial)
Abstract: 7500
Poster Presentations
INDIGO: A global, randomized, double-blind, phase III study of vorasidenib (VOR; AG-881) vs placebo in patients (pts) with residual or recurrent grade II glioma with an isocitrate dehydrogenase 1/2 (IDH1/2) mutation
Abstract: TPS2574
IDH1 mutation detection in plasma circulating tumor DNA (ctDNA) and association with clinical response in patients with advanced intrahepatic cholangiocarcinoma (IHC) from the phase III ClarIDHy study
Abstract: 4576
Ivosidenib (IVO) prior to hematopoietic cell transplant for patients with IDH1-mutant relapsed or refractory acute myeloid leukemia (R/R AML)
Abstract: 7521
Patient Resources

Fast Facts on Cholangiocarcinoma
Two-page information sheet on cholangiocarcinoma for patients and their supporters.
Download Information Sheet on CholangiocarcinomaContact Us
Medical Information Inquiries
- Agios Medical Information Call Center
- Monday – Friday 7:00am – 6:00pm CT
- with Urgent After Hours
- medinfo@agios.com
- 833-228-8474
- 901-432-3977
IVO-US-0504